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New therapeutic approaches that can accelerate neutrophil apoptosis under inﬂammatory
conditions to enhance the resolution of inﬂammation are now under study. Neutrophils
are deprived of proliferative capacity and have a tightly controlled lifespan to avoid their
persistence at the site of injury.Wehave recently described that the proliferating cell nuclear
antigen (PCNA), a nuclear factor involved in DNA replication and repair of proliferating cells
is a key regulator of neutrophil survival. The nuclear-to-cytoplasmic relocalization occurred
during granulocytic differentiation and is dependent on a nuclear export sequence thus
strongly suggesting that PCNA has physiologic cytoplasmic functions. In this review, we
will try to put into perspective the physiologic relevance of PCNA in neutrophils. We will
discuss key issues such as molecular structure, post-translational modiﬁcations, based on
our knowledge of nuclear PCNA, assuming that similar principles governing its function
are conserved between nuclear and cytosolic PCNA. The example of cystic ﬁbrosis that
features one of the most intense neutrophil-dominated pulmonary inﬂammation will be
discussed. We believe that through an intimate comprehension of the cytosolic PCNA
scaffold based on nuclear PCNA knowledge, novel pathways regulating neutrophil survival
can be unraveled and innovative agents can be developed to dampen inﬂammation where
it proves detrimental.
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INTRODUCTION
In the acute phase of inﬂammatory diseases, neutrophils are
rapidly recruited to sites of injury or infection where they
engulf and kill invading microorganisms (Witko-Sarsat et al.,
2000). Moreover, recent studies have underscored an unsus-
pected neutrophil plasticity that can inﬂuence and shape the
immune response (Mantovani et al., 2011). Neutrophil apop-
tosis, the process of programmed cell death that prevents the
release of neutrophil histotoxic contents, should be tightly reg-
ulated (Kennedy and DeLeo, 2009; Fox et al., 2010) to limit
the destructive capacity of neutrophil products to surrounding
tissues (Nathan, 2006). The subsequent recognition and phago-
cytosis of apoptotic neutrophils by macrophages is central to the
successful resolution of an inﬂammatory response. However, it
has been reported that neutrophils can phagocytosed apoptotic
cells and might participate in the clearance of apoptotic neu-
trophils at the site of inﬂammation (Esmann et al., 2010). It
is increasingly apparent that the dying neutrophil itself exerts
anti-inﬂammatory effects through modulation of surrounding
cell responses (Kobayashi et al., 2002), particularly macrophage
inﬂammatory cytokine release (Ariel and Serhan, 2012). In sev-
eral inﬂammatory diseases including arthritis (Wright et al., 2010),
vasculitis (Abdgawad et al., 2012), or cystic ﬁbrosis (CF; McKeon
et al., 2008; Moriceau et al., 2009, 2010), neutrophil apoptosis was
delayed, thus potentiating the deleterious inﬂammatory response.
Recent studies have highlighted the complexity of neutrophil
death mechanisms and uncovered the involvement of novel path-
ways (Geering and Simon, 2011). Neutrophil survival induced for
instance by cytokine such as G-CSF involves a complex gene pat-
tern as evidence by gene array studies (Drewniak et al., 2009). As an
example, we have identiﬁed the proliferating cell nuclear antigen
(PCNA) as a key element controlling neutrophil survival. In neu-
trophils, that are non-proliferating cells, PCNA localization was
strictly cytosolic and correlated with the grade of their viability
(Witko-Sarsat et al., 2010).
A SOPHISTICATED REGULATION OF APOPTOSIS IS
REQUIRED TO CONTROL NEUTROPHIL ACTIVATION
Like other cells, a neutrophil possesses both pro-survival and death
pathways, the balance of which determines its fate (Witko-Sarsat
et al., 2011). Several studies have unraveled the standard cascade of
events, which classically include mitochondrial outer membrane
permeabilization (MOMP) followed by release of cytochrome c
(that is veryweak in neutrophils) and other pro-apoptotic proteins
into the cytosol, caspase activation, DNA fragmentation, chro-
matin condensation, loss of membrane asymmetry, formation of
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apoptotic bodies (Geering and Simon, 2011; Kepp et al., 2011)
and, ﬁnally, generation of “eat me signals” that stimulate the
uptake of apoptotic cells by phagocytes (Paidassi et al., 2009).
In neutrophils, the apoptotic machinery presents speciﬁc fea-
tures that render these cells peculiar and very interesting to study
as a model in which apoptosis control is cell cycle-independent
because they cannot proliferate (Witko-Sarsat et al., 2011). Hence,
a complete cell cycle arrest was observed in band cells and seg-
mented neutrophils from bone marrow and in circulating mature
neutrophils (Theilgaard-Monch et al., 2005). Expression patterns
of apoptosis genes studied by microarray indicated that death
control occurred by the p53 pathway in promyelocytes and by
death receptor pathways in bone marrow neutrophils. Neu-
trophil apoptosis is inhibited by a continuous expression of the
short lifespan Bcl-2 homolog myeloid cell leukemia-1 (Mcl-1;
Thomas et al., 2010). It has been clearly shown that neutrophil
survival was regulated by the inducible expression of the short-
lived Mcl-1 (Moulding et al., 2001). In that respect, Mcl-1 can
be considered as a potential target to modulate neutrophil’s
fate (Milot and Filep, 2011). However, the molecular mecha-
nisms controlling this “spontaneous or constitutive” apoptosis
still remain obscure: it is not clear whether neutrophil apopto-
sis occurred because of the lack of external surviving signals or
because of its “internal clock”. It has been reported that deac-
tivation of phosphatidylinositol 3,4,5-triphosphate/Akt signaling
mediates neutrophil spontaneous death (Zhu et al., 2006). Accord-
ingly, neutrophils depleted of Phosphatase and tensin homolog
deleted on chromosome 10 (PTEN), a phosphatase that neg-
atively regulates Akt activity, live much longer than wild-type
neutrophils. Some surprising insights into neutrophil survival
mechanisms came when cyclin-dependent kinases (CDK) hap-
pened to play a key role in the regulation of neutrophil survival
(Rossi et al., 2006). Notably, CDK are implicated in the regulation
of the cell cycle and constitute targets for anti-cancer therapies
(Malumbres et al., 2009). Inhibition of CDK by roscovitine can
trigger neutrophil apoptosis by interfering with the phospho-
rylation of RNA polymerase II and with neutrophil transcrip-
tional capacities thereby inducing neutrophil apoptosis (Leitch
et al., 2012).
PCNA: A NOVEL PLAY FOR THIS FASCINATING ACTOR THAT
ESCAPES FROM NUCLEUS TO MEDIATE NEUTROPHIL
SURVIVAL
An unanticipated ﬁnding came with our discovery that PCNA,
an ancestral nuclear protein involved in DNA replication, was
present in resting neutrophil cytosol and was degraded upon
apoptosis. In fact, PCNA happened to be an actor of neutrophil
survival (Witko-Sarsat et al., 2010) but it remains to be investi-
gated whether it could regulate “the neutrophil internal clock”.
Historically, PCNA was described as an antigen for autoimmune
disease in systemic lupus erythematosus patients, detected only
in the proliferating cells (Mahler et al., 2012). The tight associa-
tion of PCNA with cancer transformation resulted in the use of
PCNA as a diagnostic and prognostic cell cycle marker in tumors
(Stoimenov and Helleday, 2009).
With the aim to start understanding the molecular mechanisms
whereby PCNA exerts its anti-apoptotic activities and how the
cytosolic PCNA scaffold is regulated,wewill next discuss key issues
based on our knowledge of nuclear PCNA, assuming that similar
principles governing its function are conserved between nuclear
and cytosolic PCNA.
A UNIQUE BUT CONSERVED TRIDIMENSIONAL STRUCTURE
Proliferating cell nuclear antigen is a ubiquitous protein that has
a unique ring-shaped structure (Krishna et al., 1994) and a highly
conserved amino acid sequence (Prosperi, 2006). PCNA has been
identiﬁed in all eukaryotes from unicellular organisms to humans.
Striking is the similarity in molecular structure between yeast and
human that share 35% amino acid sequences identity but have
highly superimposable three-dimensional structure (Stoimenov
and Helleday, 2009). Trimeric PCNA exhibits sixfold symmetry
as a result of having two globular domains in each monomer
(Figure 1). The importance of PCNA in DNA replication is tightly
linked with its ring-shaped structure that allows to slide freely
on duplex DNA (Kelman, 1997). Remarkably, PCNA mutants
that cannot form trimers failed to stimulate the polymerase Pol
δ (Jonsson et al., 1995). Deletion of the PCNA gene in the yeast
showed that PCNA was an essential protein required for DNA
replication and knocking out the PCNA gene in mice was lethal
(Kelman, 1997).
PCNA: THE SECOND TO NONE IN THE COORDINATION OF
COMPLEX BIOLOGICAL PROCESSES
One key issue is that PCNA has no known enzymatic activity but
can interact with a diverse array of proteins and cellular factors to
regulate their activities: PCNA has been named the “professional
recruiting agent”or more elegantly the“dancer with multiple part-
ners” (Maga and Hubscher, 2003). PCNA-interacting proteins can
be classiﬁed into two groups (Moldovan et al., 2007): the ﬁrst con-
sists of enzymes involved in nucleic acid metabolism, including
DNA replication [replication factor C (RFC), DNA polymerase
δ and ε, FEN-1, DNA ligase I] and repair (MutL homolog 1,
MutS homolog 2, Uracil-DNA glycosylase 2) that are localized
for the majority exclusively in nucleus. In contrast, the second
group consists of cell cycle regulatory proteins (p21/waf1/Cip1,
p57, CDK2, growth arrest and DNA damage (Gadd45), and the
myeloid-differentiation primary-response (MyD118), Mcl-1) that
localized both within the nuclei or the cytoplasmic compart-
ment depending on the cell type. Except for Mcl-1, the major
anti-apoptotic Bcl-2 homolog expressed in neutrophils (Thomas
et al., 2010), these latter PCNA partners have not been studied
in the neutrophil survival context. We have previously shown
that, in mature neutrophils, PCNA was constitutively associated
with procaspase-3, procaspase-8, procaspase-9, and procaspase-
10, presumably sequestering them within the cytosol to prevent
their activation. In line with this notion, recombinant PCNA was
shown to interfere with in vitro procaspase 9 activation (Witko-
Sarsat et al., 2010), thus strongly suggesting that PCNA association
with procaspases represents a way to block their activation.
p21/waf1 DESTABILIZED THE PCNA SCAFFOLD AND
TRIGGERED NEUTROPHIL APOPTOSIS
p21/waf1 is a well characterized PCNA partner that has been iden-
tiﬁed in a protein complex containing PCNA, cyclin, and CDK
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FIGURE 1 | Dual life of PCNA: from nucleus to cytosol. (A) PCNA is a
scaffold protein, which acts as a trimer (represented here in red–blue–green)
as shown by its molecular tridimensional structure (PDB ID: 1VYM, PyMOL
Molecular Graphics System). PCNA forms a ring-shaped complex, which can
encircle the DNA and orchestrate DNA replication and reparation. PCNA
monomers have two similar globular domains, linked by a long ﬂexible loop
called the interdomain-connecting loop that binds numerous PCNA partners
including p21/waf1. A synthetic peptide from the sequence of p21/waf1
(represented here in yellow) is bound to this interdomain-connecting loop. The
nuclear export sequence (NES) is composed of a central helix (represented
here with orange balls) localized in the inner face of the PCNA trimer. (B) In
proliferating cells such as the myeloid CD34+ precursor cells, PCNA is nuclear
as shown by PCNA immunolabeling (in red) and DNA staining with Hoechst
(in blue). The purple color results from the colocalization between PCNA and
DNA within nucleus. PCNA is a trimeric ring (represented in green), which
exerts its activity during DNA replication by braceleting DNA. PCNA has an
important role in DNA synthesis because it is part of the polymerase Pol δ
holoenzyme (represented in orange). (C) In contrast, in neutrophils, PCNA is
localized exclusively within the cytosol as shown by the red color of the
cytoplasm and the blue nuclei with its typical polylobular form. During
granulocytic differentiation, there is a nuclear-to-cytosol relocalization that
involves a NES that we have recently characterized (Bouayad et al., 2012). In
neutrophils, under pro-survival conditions, cytosolic PCNA is associated with
multiple partners, including procaspases-3, -8, -9, and -10 to prevent their
activation, and is stabilized by the treatment of neutrophils with G-CSF
(Witko-Sarsat et al., 2010). On the opposite, death signals, either directly or
indirectly can target PCNA, leading to a disruption of the PCNA scaffold and
thus triggering apoptosis (Witko-Sarsat et al., 2011). Further studies are
required to characterize PCNA structure, to identify its partners and to
understand how cytosolic PCNA can regulate neutrophil survival.
(Xiong et al., 1992;Waga et al., 1994). p21/waf1 is a p53-responsive
gene but p21 expression can also be p53-independent (Biggs and
Kraft, 1995). The p21 has two different inhibitory effects on the
entry of the cell into S-phase. One is to inhibit the kinase activ-
ity of CDK and the other is to inhibit DNA replication via an
interaction with PCNA (Goubin and Ducommun, 1995). Based
on previous studies, synthetic peptides such as the carboxy-p21
peptide (residues 141–160 on the p21/waf1 sequence) carrying
the consensus sequence for binding to the PCNA interdomain-
connecting loop (Figure 1) was shown to act as an effective
competitor for PCNA partners and to interfere with its functions
(Warbrick, 2000). Remarkably, this carboxy-p21 triggered neu-
trophil apoptosis and concomitant PCNAdegradation, in addition
to impair the capacity of G-CSF to prolong neutrophil survival
in vitro (Witko-Sarsat et al., 2010). Thus, the observation that
the carboxy-p21 triggered neutrophil apoptosis by disturbing the
PCNA scaffold clearly showed to us that PCNA is pivotal in main-
taining neutrophil survival.Whether p21/waf1 expression controls
the PCNA scaffold in neutrophils has not been investigated yet.
The expression of p21 has been shown to be downregulated dur-
ing granulocytic differentiation (Yaroslavskiy et al., 1999) and its
expression in mature neutrophils is low under resting conditions
(Klausen et al., 2004). Surprisingly, p21 mRNA has been shown
to be strongly upregulated in vivo in human neutrophils iso-
lated from bronchoalveolar lavages following LPS intratracheal
instillation (Coldren et al., 2006). Whether p21–PCNA interac-
tion could play a role in neutrophil survival will require further
investigations.
CYTOSOL AS A PHYSIOLOGIC PLAYGROUND FOR PCNA ACTION
The peculiar exclusive cytoplasmic localization was a feature of
mature neutrophils as, for instance, PCNA was detectable exclu-
sively in the nucleus of CD34+ cells or in myeloblasts isolated
from human bone marrow aspirates (Witko-Sarsat et al., 2010).
More recently we have provided evidence of an active PCNA
nuclear export that involved the chromosome region maintenance
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1 (CRM1) exportin (Turner et al., 2012). Accordingly, leptomycin
B, an inhibitor of the CRM1 exportin inhibited this PCNA relo-
calization during granulocytic differentiation of human primary
CD34+ cells or in promyelocytic cell lines (Bouayad et al., 2012).
Using enhanced green ﬂuorescent protein fusion constructs, we
demonstrated that PCNA relocalization involved a nuclear export
signal (NES) located from I11 to I23 in the PCNA sequence. How-
ever, this NES, located at the inner face of the PCNA trimer
(Figure 1) was not functional in wild-type PCNA, but instead,
was fully active and leptomycin B-sensitive in the monomeric
PCNAY114A mutant. We also provided evidence that nuclear-
to-cytoplasmic relocalization that occurred physiologically during
myeloid differentiation was essential for PCNA anti-apoptotic
activity inmature neutrophils. It is noteworthy that the PCNANES
was extremely conserved between species (Bouayad et al., 2012)
thus suggesting that this CRM1-dependent export of PCNA was
part of the physiologic PCNA trafﬁcking presumably occurring
in cells other than neutrophils, thus uncovering a novel aspect
of PCNA functions. Notably, the presence of PCNA has been
recently described in the cytosol of cancer cells (Naryzhny and
Lee, 2010).
POST-TRANSLATIONAL MODIFICATIONS OF CYTOSOLIC PCNA:
A KEY IN NEUTROPHIL SURVIVAL?
Another level of complexity in the ballet of PCNA partners within
nucleus, is the multiplicity of PCNA post-translational modiﬁca-
tions that modulate speciﬁc protein interactions (Moldovan et al.,
2007). In fact, phosphorylation (although controversial), ubiqui-
tination, sumoylation, and acetylation that have been described
for nuclear PCNA offer a great deal of options to modulate
PCNA activities (Naryzhny and Lee, 2004). In neutrophils, we
have observed that PCNA was ubiquitinated and was degraded
via the proteasome during apoptosis (Witko-Sarsat et al., 2010).
The levels of PCNA were found to time-dependently decrease
in neutrophils undergoing apoptosis regardless of whether the
triggering signaling cascade passed through the extrinsic (death
receptors) or the intrinsic pathway (mitochondria). Since pro-
teasome inhibitors reversed such a PCNA diminution, we con-
cluded that a proteasome-mediated PCNA degradation, trig-
gered along both the death receptor and mitochondrial apop-
totic cascades, was responsible for apoptosis-induced PCNA
degradation.
MODULATING PCNA SCAFFOLD IN NEUTROPHIL-DRIVEN
INFLAMMATION: THE MODEL OF CYSTIC FIBROSIS
THE PROMINENT ROLE OF NEUTROPHIL IN CYSTIC FIBROSIS
AIRWAY INFLAMMATION
Cystic ﬁbrosis which is a lethal autosomal recessive disorder caused
by mutation of the CF transmembrane regulator (CFTR) gene, is
characterized by an intense neutrophil-dominated airway inﬂam-
mation (Cantin, 1995) and a chronic bacterial colonization with
Pseudomonas aeruginosa. Plugging in small airways contributes
to the morbidity and mortality in CF (Burgel et al., 2007), lead-
ing to respiratory failure and the need for lung transplantation
(Burgel and Nadel, 2008). The prognosis is tightly linked with
the severity of the inﬂammatory process. Hence, the extraor-
dinary numbers of neutrophils accumulating within airways of
CF patients has led to the hypothesis of an innate immunity
failure (Bals et al., 1999). Today, the current treatment involves
antibiotherapy and mucolytic drugs but therapeutic interven-
tion in CF remains a challenge (Pier, 2012). Anti-inﬂammatory
drugs for CF lung disease appear to have some beneﬁcial effects
on disease progression. These agents include oral corticosteroids
and ibuprofen, as well as azithromycin, which, in addition to
its antimicrobial effects, also possess anti-inﬂammatory prop-
erties. Inhaled corticosteroids, antioxidants, nutritional sup-
plements, and protease inhibitors have a limited impact on
the disease. Adverse effects limit therapy with oral corticos-
teroids and ibuprofen (Narasimhan and Cohen, 2011). Hence,
the lack of promising candidate emphasizes the need for fresh
approaches in the management of airway inﬂammation in CF, for
instance by targeting neutrophil apoptosis in combination with
antibiotherapies.
Previous studies on CF patient’s neutrophils indicated func-
tional disturbances in bacterial phagocytosis, killing, and other
effector functions (Downey et al., 2009). Because of the extreme
heterogeneity of CF patients in terms of infectious status (Witko-
Sarsat et al., 1999), the comparisons of experiments and results
are difﬁcult. Indeed, we have previously shown that neutrophils
from CF parents who were heterozygous for CFTR mutation, had
also disturbed neutrophil functions thus suggesting the possibil-
ity of an innate neutrophil defect in CF (Witko-Sarsat et al., 1996;
Moriceau et al., 2010). Accordingly, a recent study has provided
evidence that the absence of the CFTR from myeloid-derived
cells slows the resolution of inﬂammation (Bonﬁeld et al., 2012).
Gene-expression patterns of neutrophils from clinically stable and
healthy controls have shown dramatic differences (Adib-Conquy
et al., 2008). This was consistent with a perturbed “inﬂammatory
program” in CF neutrophils (Hayes et al., 2011), which remains to
be investigated (Tirouvanziam et al., 2008). It should also be men-
tioned that perpetuation of inﬂammation in the CF airway may
also be ampliﬁed by defective macrophage clearance mechanisms.
It has been shown that persistence of infection in CF was partly
due to ineffective uptake and killing of pathogens due to a defec-
tive macrophage innate response (Wright et al., 2009). Notably,
a defect in apoptotic cell clearance has also been reported in CF
(Vandivier et al., 2002).
DYSREGULATED NEUTROPHIL APOPTOSIS: A POTENTIAL TARGET
FOR THERAPEUTIC INTERVENTION
Given the number of neutrophils in CF airways (Danel et al.,
1996; Figure 2A), late neutrophil apoptosis could have devastating
consequences. This neutrophil-dominated airway inﬂammation
typical of the CF condition is representative of a chronic but
active inﬂammatory process with neutrophil persistence suggest-
ing a defect in apoptotic neutrophil clearance by macrophages
(Figure 2B). Indeed, we (Moriceau et al., 2010) and others (McK-
eon et al., 2008) reported that neutrophils from CF patients
undergo delayed apoptosis and have decreased levels of the pro-
apoptotic protein Bax (Dibbert et al., 1999), thereby slowing their
removal by macrophages and potentiating airway inﬂammation.
In an attempt to modulate the delayed apoptosis in neutrophils
from CF patients, roscovitine was used at 10 μM to restore
normal apoptosis levels for CF PMN (Moriceau et al., 2010).
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FIGURE 2 | Proliferating cell nuclear antigen (PCNA) expression in
neutrophils within airways from CF patients. (A) Neutrophils and
macrophages from bronchoalveolar lavages (BAL) from a control donor and
from a patient with CF. The control BAL was composed mainly of alveolar
macrophages. In contrast, in BAL from CF 95% of the cells are neutrophils
either viable or apoptotic. Few macrophages and lymphocytes are present
as well as cell debris and mucus (Giemsa stain ×630 original magniﬁcation).
(B) Neutrophil-dominated inﬂammation in lung explants from a CF patient.
Acute inﬂammation within the lung in CF patient with characteristic
histologic features: (1) inﬂammatory inﬁltrate with neutrophils (black circle
and arrow) and lymphocytes in the lamina propria, (2) transepithelial
neutrophil migration (red circles), and (3) accumulation of degenerating and
apoptotic neutrophils in the lumen (red arrow; Hematoxylin–Eosin–Safran
staining ×200 original magniﬁcation). Lung explant specimens from CF
patients were obtained at transplantation (Hôpital Européen Georges
Pompidou). (C) Immunoperoxidase labeling of PCNA on parafﬁn sections of
lung explants from a CF patient. Labeling was performed using a rabbit
polyclonal anti-PCNA antibody (Ab5, diluted 1:100, Calbiochem) and
immunoperoxidase detection (Dako) as previously described (Moriceau
et al., 2009; ×630 original magniﬁcation). The airway lumen contents
neutrophils expressing PCNA (upper left panel). Neutrophils within vessels
(red arrow, upper right panel, red circle on the lower left panel) expressed
high amounts of PCNA as did neutrophils found in the epithelium (red circle
on lower right panel). This strong PCNA expression in neutrophil cytosol
contrasts with the lack of labeling observed in cells present in the lamina
propria, including ﬁbroblasts and lymphocytes. Similar observations were
made in lung explants from four CF patients.
Whether CDK-mediated survival pathway could crosstalk with
the PCNA scaffold is currently unknown and would require more
investigations.
We recently identiﬁed coronin-1A (Grogan et al., 1997) as a
cytosolic protein overexpressed in CF neutrophils, a ﬁnding that
was consistent with its anti-apoptotic function (Moriceau et al.,
2009). Coronin-1 expression investigated by immunohistochem-
istry of pulmonary tissues obtained from CF patients during
transplantation clearly showed a strong coronin-1A expression in
neutrophils at the site of inﬂammation (Moriceau et al., 2009).
Similar immunohistochemistry labeling of PCNA in neutrophils
within the airway lumen showed a great variation in their PCNA
contents reﬂecting their different apoptosis rates (Figure 2C). In
contrast, the cytoplasm of neutrophils present within the mucosa,
lamina propria and vessels were strongly labeled thus indicating
their survival state (Figure 2C). These observations suggest that
PCNA was highly expressed in neutrophils inﬁltrating the lung
of CF patients and might play a role in neutrophil survival at
the site of inﬂammation. Whether PCNA could be associated to
coronin-1A is currently unknown but should require more inves-
tigation. Investigation of cytosolic PCNA within neutrophils at
sites of inﬂammation (for instance in vasculitis or rheumatoid
arthritis) should also be explored.
Strategies aiming at potentiating neutrophil apoptosis by tar-
geting the PCNA scaffold in CF have to be carefully investigated
and could be combined with other anti-inﬂammatory or anti-
infectious therapeutic strategies to achieve a maximum efﬁcacy
in term of dampening neutrophil-driven inﬂammation. It might
be possible to adjust this type of therapy to avoid any risk of
neutropenia-induced infection.
CONCLUSION
Highlighting peculiar pathways used by neutrophils to con-
trol their survival (Geering and Simon, 2011) are of pivotal
importance for the development of novel anti-inﬂammatory
strategies (Dufﬁn et al., 2010). Even in the absence of prolifera-
tion, PCNA seems to have a conservative function for preserving
neutrophil’s life. This particular cytosolic PCNA localization
strongly suggests that this could be harnessed for therapeutic
purposes when neutrophils would be out of control such as
in sustained inﬂammation. This will be our main challenge to
exploit all the data on nuclear PCNA gathered during more
than ﬁve decades of work, and try to be creative to under-
stand how the enigmatic PCNA scaffold participates to neutrophil
survival.
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